OSE Immunotherapeutics SA (FRA:6OP)

Germany flag Germany · Delayed Price · Currency is EUR
4.338
+0.024 (0.56%)
Last updated: Feb 20, 2026, 8:02 AM CET
Market Cap96.41M -37.3%
Revenue (ttm)1.78M -95.8%
Net Income-32.52M
EPS-1.48
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume250
Average Volumen/a
Open4.338
Previous Close4.314
Day's Range4.338 - 4.338
52-Week Range4.272 - 7.165
Betan/a
RSI39.02
Earnings DateMar 27, 2026

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 64
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6OP
Full Company Profile

Financial Performance

Financial Statements